Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28921579 | 0.98 | CA2 (0.56) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL515105 | 0.93 | CA2 (0.67) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL28232679 | 0.90 | CA2 (0.48) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL28466819 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7701880 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL27602959 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL919412 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL919763 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL9395527 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 | |
| SCHEMBL2114617 | 0.88 | CA2 (0.59) | CA2MAPK1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372581-B1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | DAIKIN IND LTD (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-10894770-B2 | Fullerene derivative and n-type semiconductor material | DAIKIN INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20180282274-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | DAIKIN INDUSTRIES, LTD. (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3372581-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | Daikin Industries, Ltd. (JP) | 2018-09-12 | — | — | EP | disclosed |
| CN-108137498-A | Fullerene derivate and n-type semiconductor | 大金工业株式会社 | 2018-06-08 | — | — | CN | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | CA2 2631/4885MAPK1 895/4885CA1 2516/4885 |
| US-10894770-B2 | Fullerene derivative and n-type semiconductor material | SUN2, NES, L1CAM | CA2 3050/4885MAPK1 3421/4885CA1 2713/4885 |
| US-20180282274-A1 | FULLERENE DERIVATIVE AND n-TYPE SEMICONDUCTOR MATERIAL | SUN2, NES, L1CAM | CA2 3050/4885MAPK1 3421/4885CA1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.